

December 23, 1998

Baxter Pharmaceutical Products, Inc.  
Attention: Priya Jambhekar  
110 Allen Road  
Liberty Corner, NJ 07938-0804



Dear Madam:

This is in reference to your abbreviated new drug application dated July 31, 1995, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Propofol Injectable Emulsion, 1% (10 mg/mL).

Reference is also made to your amendments dated November 19, 1996; and March 4, October 15 and November 24, 1998.

We have completed the review of this abbreviated application and have concluded that, based upon the information you have presented to date, the drug is safe and effective for use as recommended in the submitted labeling. Therefore, the application is **tentatively approved**. This determination is based upon information available to the Agency at this time, (i.e., information in your application and the status of current good manufacturing practices of the facilities used in the manufacturing and testing of the drug product), and is subject to change on the basis of new information that may come to our attention. The listed reference drug product upon which you have based your application is subject to a periods of patent protection and market exclusivity. Therefore, final approval of your application may not be made effective pursuant to 21 U.S.C. 355(j)(5)(B) and (D) of the Act until the latter period has expired, i.e., March 22, 2015.

Please provide the Agency, at least 60 but not more than 90 days prior to March 22, 2015, an amendment to this application. This amendment should identify changes, if any, in the conditions under which the product was tentatively approved, and should include updated information such as final printed labeling updated to reflect the change in ownership of this application, and chemistry, manufacturing, and controls data as appropriate. An amendment should be submitted at that time even if none of these changes were made. This submission should be designated as a MINOR AMENDMENT in your cover letter. In addition to, or instead of, the amendment requested above, the Agency may, at any time prior to the final date of approval, request that you submit an amendment containing the information described above.

Failure to submit such an amendment requested by the Agency will prompt a review of the application which may result in rescission of this tentative approval letter.

Any significant changes in the conditions outlined in this abbreviated application requires Agency approval before the changes may be made effective.

Prior to issuance of a final approval letter by the Agency, your product will not be deemed approved for marketing under 21 U.S.C. 355 and will not be listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" list, published by the Agency. Should you believe that there are grounds for issuing the final approval letter prior to March 22, 2015, you should amend your application accordingly.

At the time you submit any amendments, you should contact Kassandra Sherrod, Project Manager, at (301) 827-5849, for further instructions.

The introduction or delivery for introduction into interstate commerce of the drug before the effective approval date is prohibited under 21 U.S.C. 331(d).

Sincerely yours,

Douglas L. Sporn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research